Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
作者： J Cortes , D-W Kim , E Raffoux , G Martinelli , E Ritchie
DOI: 10.1038/LEU.2008.221
关键词: Myeloid 、 Chronic myelogenous leukemia 、 Surgery 、 Gastroenterology 、 Dasatinib 、 Internal medicine 、 Febrile neutropenia 、 Population 、 Imatinib mesylate 、 Medicine 、 Myeloid leukemia 、 Tolerability
摘要: Dasatinib is an inhibitor of BCR-ABL and SRC-family kinases for patients with imatinib-resistant or -intolerant chronic myelogenous leukemia (CML). In this international phase II trial, dasatinib was administered orally (70 mg twice daily) to myeloid blast (MBP, n=109) lymphoid (LBP, n=48) CML. After a minimum follow-up 12 months (range 0.03-20.7 months), major hematologic responses were induced in 34% (MBP-CML) 35% (LBP-CML) patients. Major cytogenetic attained 33% 52% complete 26 46%, respectively. Median progression-free survival 6.7 3.0 months. overall 11.8 5.3 Overall, had acceptable tolerability. Fluid retention events more frequent the MBP-CML than LBP-CML cohort: pleural effusion occurred 36 13% (all grades) 15 6% (grades 3/4), Other non-hematologic side effects primarily grade 1/2; 3/4 recorded
nature.com
elsevier.com
utsystem.edu
researchgate.net 参考文章(30)
Jyoti Wadhwa, Richard M. Szydlo, Jane F. Apperley, Andrew Chase, Marco Bua, David Marin, Eduardo Olavarria, Edward Kanfer, John M. Goldman, Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood. ,vol. 99, pp. 2304- 2309 ,(2002) , 10.1182/BLOOD.V99.7.2304
Y. Hu, S. Swerdlow, T. M. Duffy, R. Weinmann, F. Y. Lee, S. Li, Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice Proceedings of the National Academy of Sciences of the United States of America. ,vol. 103, pp. 16870- 16875 ,(2006) , 10.1073/PNAS.0606509103
Nicholas J. Donato, Ji Yuan Wu, Jonathan Stapley, Gary Gallick, Hui Lin, Ralph Arlinghaus, Moshe Talpaz, BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. ,vol. 101, pp. 690- 698 ,(2003) , 10.1182/BLOOD.V101.2.690
Agata Klejman, Steven J Schreiner, Malgorzata Nieborowska-Skorska, Artur Slupianek, Matthew Wilson, Thomas E Smithgall, Tomasz Skorski, The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells The EMBO Journal. ,vol. 21, pp. 5766- 5774 ,(2002) , 10.1093/EMBOJ/CDF562
A Hochhaus, M Baccarani, M Deininger, J F Apperley, J H Lipton, S L Goldberg, S Corm, N P Shah, F Cervantes, R T Silver, D Niederwieser, R M Stone, H Dombret, R A Larson, L Roy, T Hughes, M C Müller, R Ezzeddine, A M Countouriotis, H M Kantarjian, Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. ,vol. 22, pp. 1200- 1206 ,(2008) , 10.1038/LEU.2008.84
Moshe Talpaz, Neil P. Shah, Hagop Kantarjian, Nicholas Donato, John Nicoll, Ron Paquette, Jorge Cortes, Susan O'Brien, Claude Nicaise, Eric Bleickardt, M. Anne Blackwood-Chirchir, Vishwanath Iyer, Tai-Tsang Chen, Fei Huang, Arthur P. Decillis, Charles L. Sawyers, Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias The New England Journal of Medicine. ,vol. 354, pp. 2531- 2541 ,(2006) , 10.1056/NEJMOA055229
Louis J. Lombardo, Francis Y. Lee, Ping Chen, Derek Norris, Joel C. Barrish, Kamelia Behnia, Stephen Castaneda, Lyndon A. M. Cornelius, Jagabandhu Das, Arthur M. Doweyko, Craig Fairchild, John T. Hunt, Ivan Inigo, Kathy Johnston, Amrita Kamath, David Kan, Herbert Klei, Punit Marathe, Suhong Pang, Russell Peterson, Sidney Pitt, Gary L. Schieven, Robert J. Schmidt, John Tokarski, Mei-Li Wen, John Wityak, Robert M. Borzilleri, Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. Journal of Medicinal Chemistry. ,vol. 47, pp. 6658- 6661 ,(2004) , 10.1021/JM049486A
Francois Guilhot, Jane Apperley, Dong-Wook Kim, Eduardo O. Bullorsky, Michele Baccarani, Gail J. Roboz, Sergio Amadori, Carmino A. de Souza, Jeffrey H. Lipton, Andreas Hochhaus, Dominik Heim, Richard A. Larson, Susan Branford, Martin C. Muller, Prasheen Agarwal, Ashwin Gollerkeri, Moshe Talpaz, Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. ,vol. 109, pp. 4143- 4150 ,(2007) , 10.1182/BLOOD-2006-09-046839
Paul M. Derderian, Hagop M. Kantarjian, Moshe Talpaz, Susan O'Brien, Ann Cork, Elihu Estey, Sherry Pierce, Michael Keating, Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis The American Journal of Medicine. ,vol. 94, pp. 69- 74 ,(1993) , 10.1016/0002-9343(93)90122-6
Thomas B. Sneed, Hagop M. Kantarjian, Moshe Talpaz, Susan O'Brien, Mary Beth Rios, B. Nebiyou Bekele, Xian Zhou, Debra Resta, William Wierda, Stefan Faderl, Francis Giles, Jorge E. Cortes, The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. ,vol. 100, pp. 116- 121 ,(2004) , 10.1002/CNCR.11863